Revolution Medicines director gets new equity awards

Revolution Medicines, Inc. reported that director Kim Lorence H. received new equity compensation awards.

Rhea-AI Filing Summary

Revolution Medicines, Inc. reported that director Kim Lorence H. received new equity compensation awards. The director was granted 1,191 shares of Common Stock in the form of restricted stock units at no cash cost, increasing direct holdings to 74,281 shares. In addition, the director received a stock option for 3,127 shares of Common Stock with an exercise price of $162.99 per share, expiring on June 18, 2036. The option vests in full on the earlier of the first anniversary of June 18, 2026 or immediately before the next Annual Meeting after the grant date, as long as the director continues as a service provider under the company’s 2020 Plan.

Insider Trade Summary

Grant/Award: 4,318 shares

Grant/Award 2 txns

Insider Kim Lorence H.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	3,127	$0.00	$0.00
Grant/Award	Common Stock	1,191	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 3,127 contracts (Direct); Common Stock — 74,281 shares (Direct)

Footnotes (2)

1. F1. Includes 1,191 restricted stock units.
2. F2. Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 18, 2026 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date.

Key Figures

Restricted stock units granted: 1,191 shares Stock options granted: 3,127 options Option exercise price: $162.99/share +3 more

6 metrics

Restricted stock units granted 1,191 shares RSUs included in common stock holdings for director

Stock options granted 3,127 options Right to buy common stock

Option exercise price $162.99/share Strike price for stock option grant

Option expiration date June 18, 2036 Expiration of director’s stock option

Shares held after grant 74,281 shares Director’s direct common stock holdings after awards

Underlying option shares 3,127 shares Common stock underlying the stock option

Key Terms

restricted stock units, Stock Option (Right to Buy), Annual Meeting, 2020 Plan

4 terms

restricted stock units financial

"Includes 1,191 restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) with 3,127 shares underlying"

Annual Meeting financial

"vest in full on the earlier of the first anniversary or immediately prior to the Annual Meeting"

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

2020 Plan financial

"subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Revolution Medicines (RVMD) report for Kim Lorence H.?

Revolution Medicines reported that director Kim Lorence H. received equity awards, including 1,191 restricted stock units and a stock option for 3,127 shares. These grants are compensation, not open-market purchases or sales, and increase the director’s reported equity stake in the company.

How many Revolution Medicines (RVMD) shares does the director hold after this Form 4?

After the reported grants, director Kim Lorence H. holds 74,281 shares of Revolution Medicines common stock directly. This total includes 1,191 restricted stock units that are part of the reported equity award and remain subject to vesting conditions over time.

What are the terms of the new stock options granted by Revolution Medicines (RVMD)?

The stock option covers 3,127 shares of Revolution Medicines common stock at an exercise price of $162.99 per share and expires on June 18, 2036. It represents a right to buy shares in the future, subject to vesting and continued service conditions.

When do the new Revolution Medicines (RVMD) stock options for the director vest?

The stock options vest in full on the earlier of the first anniversary of June 18, 2026, or immediately before the Annual Meeting following the grant date. Vesting requires the director to remain a service provider under the company’s 2020 equity incentive plan through that date.

Are the Revolution Medicines (RVMD) equity awards to the director open-market share purchases?

No, the reported transactions are compensation-related grants, not open-market purchases. The Form 4 classifies both the restricted stock units and stock options as awards acquired at no cash cost, reflecting standard director equity compensation rather than trading activity in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 05:57 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kim Lorence H.

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DR

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2026		A		1,191	A	$0	74,281(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$162.99	06/18/2026		A		3,127		(2)	06/18/2036	Common Stock	3,127	$0	3,127	D

Explanation of Responses:

1. Includes 1,191 restricted stock units.

2. Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 18, 2026 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date.

	/s/ Jack Anders, as Attorney-in-fact for Lorence H. Kim	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)